[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 1,746
Citations 0
Correction
November 19, 2014

Drug Derivation Clarified

Author Affiliations
 

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2014;312(19):2045. doi:10.1001/jama.2014.14363

In the Viewpoint entitled “Drugs for Macular Degeneration, Price Discrimination, and Medicare’s Responsibility Not to Overpay” published in the July 2, 2014, issue of JAMA (2014;312[1]:23-24. doi:10.1001/jama.2014.6672), the description of ranibizumab as the Fab portion of bevacizumab in the second paragraph was not accurate. The sentence should have read: “After bevacizumab was introduced, the manufacturer, Genentech, received approval from the US Food and Drug Administration (FDA) for a genetically engineered variant of the Fab portion of bevacizumab to be used in small doses intraocularly to treat neovascular AMD.” The article was corrected online.

×